80wk Uptrend — rising+above (sma 25.47 vs px 39.11)
200wk Uptrend — rising+above (sma 31.28 vs px 39.11)
Funds Accumulating — momZ +1.75 · 2.14→2.52
Short Squeeze Setup — velZ +1.71 · age 21w×1.00 · 10.07%
Founder-Led — founder/CEO led
About Celldex Therapeutics Inc
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Read full Trend Edge analysis →
Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
IPO Date: March 10, 2008
Headquarters: Perryville III Building, Hampton, NJ, United States, 08827
Founder-Led: Yes — Anthony Marucci (Founder, President, CEO & Director), Tibor Keler (Founder, Chief Scientific Officer & Executive VP)
Key Metrics
Current Price
$39.11
Market Cap
$3.06B
Float
72.5M
Shares Outstanding
78.5M
Price/Sales (TTM)
3,537.13
vs. Analyst Target
+47.1% to analyst PT
Operating Margin (TTM)
-562900.00%
Revenue (TTM)
$865,000
Dividend Rate
None
Analyst Target Price
$57.53 (15 analysts)
Financial History
Annual Revenue & Earnings History
Year
Revenue
Net Income
Gross Profit
EBITDA
2020
$7.4M
-$59.8M
-$35.1M
-$45.6M
2021
$4.7M
-$70.5M
-$48.7M
-$66.1M
2022
$2.4M
-$112M
-$79.9M
-$104M
2023
$6.9M
-$141M
-$111M
-$139M
2024
$7.0M
-$158M
-$157M
-$155M
2025
$1.5M
-$259M
$1.5M
-$255M
Recent Quarterly Revenue & Net Income
Quarter
Revenue
Net Income
Jun 2025
$730,000
-$56.6M
Sep 2025
N/A
-$67.0M
Dec 2025
$75,000
-$81.4M
Mar 2026
$15,000
-$78.7M
Ownership & Float
Insider Ownership
0.3%
Institutional Ownership
95.9%
Short Float
10.1%
% of All Funds Holding
2.52%
Number of Funds Holding
207
Current Moving Averages
Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.
Timeframe
SMA
Value
Trend Context
Weekly
10-Week SMA
$33.25
Near-term / short-term trend
Weekly
40-Week SMA
$29.10
Medium-term trend
Weekly
80-Week SMA
$25.47
Cyclical trend (business cycle)
Weekly
200-Week SMA
$31.28
Secular trend (multi-year)
Monthly
10-Month SMA
$30.79
Near-term monthly trend
Monthly
20-Month SMA
$26.37
Medium-term monthly trend
Monthly
40-Month SMA
$30.21
Secular monthly trend
Volume Shelves — Support & Resistance
Trend Edge identifies volume shelves: price zones where historically elevated trading volume
creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative
volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.
Price Level
Type
Volume Ratio
Age
$31.10
support
1.36x
0 months ago
$29.40
support
1.13x
2 months ago
$21.90
support
1.32x
9 months ago
$41.00
resistance
1.80x
21 months ago
Historical Earnings Reactions (118 events)
Timeframe
Avg Return
Median
Win Rate
Best
Worst
Gap
-0.47%
0.00%
42.37%
10.41%
-21.31%
1 Day
-0.18%
0.00%
45.76%
17.45%
-20.99%
1 Week
-0.65%
-1.68%
41.53%
44.98%
-26.42%
2 Weeks
-1.05%
-0.27%
46.61%
38.24%
-49.64%
1 Month
-0.37%
-2.08%
45.30%
89.84%
-47.90%
Next earnings: August 6, 2026 (25 days away)
Seasonality & Day-of-Week Patterns
Monthly Seasonality
Month
Avg Return
Win Rate
Samples
Jan
12.3%
55.0%
40
Feb
-0.4%
42.5%
40
Mar
0.6%
47.5%
40
Apr
0.3%
50.0%
40
May
-2.2%
27.5%
40
Jun
14.6%
51.2%
41
Jul
-1.2%
42.5%
40
Aug
-2.8%
37.5%
40
Sep
-1.8%
32.5%
40
Oct
0.5%
50.0%
40
Nov
5.8%
57.5%
40
Dec
-0.8%
45.0%
40
Day-of-Week Tendencies
Day
Avg Return
Win Rate
Samples
Monday
-0.18%
39.5%
1907
Tuesday
0.07%
42.0%
2075
Wednesday
0.21%
42.2%
2073
Thursday
0.15%
42.3%
2033
Friday
0.27%
42.5%
2022
Top Institutional Holders
Institutional holder breakdown coming soon.
Total institutional ownership: 95.9%
Insider Transactions — Smart Summary
Total insider ownership: 0.3%
Founder-led management: Anthony Marucci (Founder, President, CEO & Director), Tibor Keler (Founder, Chief Scientific Officer & Executive VP)
Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Celldex Therapeutics Inc
(CLDX) powered by Claude Opus — Anthropic's most capable AI model.
The analysis covers five layers:
technical analysis (near-term, medium-term, cyclical, and secular trend, momentum,
volume shelf support and resistance, breakout and breakdown signals),
qualitative analysis (business model, competitive moat, sector dynamics),
insider sentiment (buy and sell signals from executive and director transactions),
share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and
fundamental analysis (valuation, revenue growth, profit margin, earnings quality).
AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit,
stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward.
Whether you are building a long position, initiating a short, or looking for a reversal setup,
AI Consult identifies the highest-probability signal from the current trend.